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The rare autoinflammatory disease mevalonate kinase deficiency (MKD, which includes
HIDS and mevalonic aciduria) is caused by recessive, pathogenic variants in the
MVK gene encoding mevalonate kinase. Deficiency of this enzyme decreases the
synthesis of isoprenoid lipids and thus prevents the normal post-translational prenylation
of small GTPase proteins, which then accumulate in their unprenylated form. We
recently optimized a sensitive assay capable of detecting unprenylated Rab GTPase
proteins in peripheral blood mononuclear cells (PBMCs) and showed that this assay
distinguished MKD from other autoinflammatory diseases. We have now analyzed
PBMCs from an additional six patients with genetically-confirmed MKD (with different
compound heterozygous MVK genotypes), and compared these with PBMCs from
three healthy volunteers and four unaffected control individuals heterozygous for the
commonest pathogenic variant, MVKV377I. We detected a clear accumulation of
unprenylated Rab proteins, as well as unprenylated Rap1A by western blotting, in
all six genetically-confirmed MKD patients compared to heterozygous controls and
healthy volunteers. Furthermore, in the three subjects for whom measurements of
residual mevalonate kinase activity was available, enzymatic activity inversely correlated
with the extent of the defect in protein prenylation. Finally, a heterozygous MVKV377I
patient presenting with autoinflammatory symptoms did not have defective prenylation,
indicating a different cause of disease. These findings support the notion that the extent
of loss of enzyme function caused by biallelic MVK variants determines the severity of
defective protein prenylation, and the accumulation of unprenylated proteins in PBMCs
may be a sensitive and consistent biomarker that could be used to aid, or help rule out,
diagnosis of MKD.
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INTRODUCTION
Mevalonate kinase deficiency (MKD) is a rare, autosomal
recessive, autoinflammatory disorder caused by pathogenic
variants in the MVK gene (OMIM 251170) encoding the
metabolic enzymemevalonate kinase (MK) (1, 2). The symptoms
of MKD usually appear in early childhood. The milder end of the
clinical spectrum is characterized by recurrent episodes of high
fever with abdominal pain, lymphadenopathy, vomiting, diarrhea
and gastrointestinal inflammation, rashes, and debilitating joint
pain. Many patients have high serum concentrations of IgD and
IgA (hence the alternative name hyperimmunoglobulinaemia
D and periodic fever syndrome, or HIDS; OMIM 260920)
(3, 4). The more severe cases of MKD (known as mevalonic
aciduria; OMIM 610377) also present with neurological and
developmental abnormalities, and risk of premature death from
complications including pulmonary failure (5).
Decreased activity of the MK enzyme (ATP:mevalonate 5-
phosphotransferase; EC 2.7.1.36) leads to intracellular depletion
of lipid precursors that are essential for the post-translational
prenylation of proteins, particularly small GTPase proteins such
as those of the Rab family of GTPases (6). It was therefore
proposed that protein prenylation is defective in MKD and
could be the underlying cause of inflammation (7–9), however
direct evidence for defective prenylation in patient samples has
been lacking. Furthermore, diagnostic biochemical features of
MKD are not always reliable: elevated urinary mevalonic acid
levels are only detected during a fever episode and raised serum
IgD or IgA is not present in all patients (10). Genetic analysis
to detect homozygous or compound heterozygous variants in
MVK that are pathogenic or likely pathogenic offers the most
reliable diagnosis, although this does not indicate whether
previously unreported variants actually give rise to functionally
deficient MK enzyme. We recently developed a method to
detect subtle changes in the prenylation of Rab GTPase proteins
(11, 12) and showed in three patients for the first time that
prenylation of Rab proteins, as well as Rap1A, is indeed defective
in peripheral blood mononuclear cells (PBMCs) from MKD
and could be a biomarker that distinguishes this disease from
other autoinflammatory disorders with similar clinical features
(13). However, it remains to be confirmed whether this assay
consistently identifies MKD in patients with diverse MVK
genotypes. In this study, we analyzed an additional six patients
with genetically-confirmed MKD and different compound
heterozygousMVK genotypes, four healthy individuals that were
heterozygous for the commonest pathogenic variant MVKV377I ,
one patient with autoinflammatory disease but heterozygous for
MVKV377I , and three healthy controls.
METHODS
Participants
The study was approved by the Sydney Children’s
Hospitals Network Human Research Ethics Committee
Abbreviations: GGTase, geranylgeranyltransferase; MKD, mevalonate kinase
deficiency; MK, mevalonate kinase (protein); MVK, mevalonate kinase (gene);
HIDS, Hyper IgD and periodic fever syndrome.
(HREC/18/SCHN/403) and participant details are summarized
in Supplementary Table 1. Healthy control volunteers
were adult Caucasian males. Patients P1–P4 were adults,
randomly selected from a well-described cohort in Nijmegen,
the Netherlands (14). All 4 individuals were compound
heterozygous for biallelic pathogenic or likely pathogenic
variants in MVK, having the most common pathogenic variant
MVKV377I on one allele and a point mutation (H20P, I268T,
G326R) or undetermined insertion/deletion on the other allele
(genetic details summarized in Supplementary Table 2). P1
(MVKV377I/H20P), an adult female, originally presented with
classical HIDS phenotype (age of onset 2 months, inflammatory
attacks lasting 5–6 days, every 4–6 weeks) and was receiving
long-term etanercept treatment at the time of blood sampling.
P2 (MVKV377I/I268T), an adult male, originally presented
with typical symptoms of inflammatory episodes of headache,
abdominal pain, arthritis, skin lesions, lymphadenopathy,
hepatomegaly, and splenomegaly from 6 months of age. He
was receiving canakinumab treatment at the time of blood
sampling. P3 (MVKV377I/G326R) was an adult female who
showed very classical HIDS presentation with disease onset
at 3 months of age, fever episodes lasting 5 days, every 2–3
weeks. She was on canakinumab treatment at time of blood
draw. P4 (MVKV377I/indel), an adult male, presented at 6 years
of age with episodes of arthralgia/myalgia, skin lesions, arthritis,
lymphadenopathy, and vomiting lasting 7–10 days every 8 weeks.
He was not on any anti-inflammatory treatment at the time of
blood sampling.
Patients P5, P6, and P7, identified in Australia, had a clinical
history of autoinflammatory disease. P5, a young adult male,
had periodic episodes of fever, polyarthralgias, abdominal pain,
and diarrhea every month from 6 months of age. He had no
family history of note and, at 15 years of age, was diagnosed
as compound heterozygous for MVK variants (MVKV377I and a
novel, likely pathogenic duplication/insertion in exon 5 leading
to insertion of 2 amino acids; Supplementary Table 2). His
symptomatology improved with age and symptoms became
less frequent. He had moderate response to anti-IL-1 therapy,
which was given for 2 years, and was being managed with
on-demand NSAIDs. P6, an adult female, also carried the
pathogenic MVKV377I variant sequence on one allele, but lacked
genetic diagnosis of a specific autoinflammatory disease. She
had episodic large joint arthritis, intermittent macular rash,
with fevers, lymphadenopathy, and mild splenomegaly since 15
years of age. She did not respond to multiple disease-modifying
anti-rheumatic medications including low dose steroids but
eventually had complete response to anti IL-1 therapy (anakinra).
She had a daughter who was diagnosed with juvenile idiopathic
arthritis at 4 years of age. P7 was the daughter of non-
consanguineous parents of European ancestry. At 5 years of
age, she diagnosed with mild dystonic cerebral palsy. During
the next 2 years, she developed a periodic fever pattern
cycling on a 2–4 weekly basis, with temperatures of 39–
40◦C associated with significant elevations in inflammatory
markers, e.g., CRP and ESR. At 6 years of age, a diagnosis
of a monogenic periodic fever syndrome was entertained and
a short course of 1 mg/kg oral prednisolone given during a
febrile episode resulted in a complete ablation of the dystonic
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posturing and neurological symptoms. Subsequent investigations
demonstrated persistently elevated IgD titres (721–803 mg/L
RR<159) and mild elevation of urinary mevalonic acid. Whole
exome sequencing revealed biallelic, pathogenic MVK variants
(MVKV377I/Y114Ifs
∗71) inherited from each heterozygous parent
(Supplementary Table 2) and a maternally inherited variant of
the TOR1A gene (NM_000113 c.962C>T; p.Thr321Met). The
mother had no clinical features of dystonia and had a normal
neurological examination.
In vitro Prenylation (IVP) Assay
All subjects gave written informed consent in accordance with the
Declaration of Helsinki, prior to obtaining fresh peripheral blood
samples. All samples were drawn whilst individuals were without
inflammatory flares. PBMCs were isolated by centrifugation over
Ficoll; cells from P1, P2, P3, P4 collected in Nijmegen, the
Netherlands, were frozen in fetal calf serum with 10% DMSO
prior to shipping to Garvan Institute, Australia, on dry ice
whereas PBMCs from P5, P6, P7 were isolated by centrifugation
over Ficoll then washed twice with PBS, snap-frozen as cell pellets
and stored at−80◦C.
Frozen pellets of viable cells that were thawed and centrifuged
(P1–P4), or snap-frozen cell pellets (P5–P7), were lysed by
sonication in∼100 µl prenylation buffer (50mMHEPES pH 7.2,
50mM NaCl, 2mM MgCl2, 100µM GDP, 1x Roche complete
EDTA-free protease inhibitor cocktail). Protein was quantified
using a BCA assay (Pierce) then in vitro prenylation assays to
detect unprenylated Rab GTPases were performed as previously
described (11). Briefly, DTT was added to 50 µg cell lysate
to a final concentration of 2mM, with final concentrations of
2µM Rab GGTase, 2µM recombinant Danio rerio Rab escort
protein-1 (REP-1), 0.5µM B-GPP in a total volume of ∼50
µL and reactions incubated for 5 h at room temperature. In
vitro prenylated (i.e., biotinylated) Rab proteins were detected
on PVDF blots using streptavidin-680RD (LiCOR). A narrow
doublet (often appearing as a broad singlet) of endogenous
biotinylated 75 kDa protein was used as a sample loading
control. Blots were also analyzed for unprenylated Rap1A by
western blotting using goat anti-Rap1A (sc-1482) as previously
described (11).
RESULTS
Analysis of frozen, viable PBMCs obtained from 4 MKD
patients in the Netherlands (P1–P4) demonstrated a clear
accumulation of unprenylated Rab GTPases and unprenylated
Rap1A (Figure 1A), compared to PBMCs from a healthy
control and two unaffected heterozygous carriers of MVKH20N
and MVKV377I variants [the latter described previously, (13)].
Patients P1, P2, and P4, with MVKV377I/H20P, MVKV377I/I268T ,
and MVKV377I/indel genotypes, respectively, appeared to have
a more severe defect in prenylation than patient P3, with the
MVKV377I/G326R genotype. MK enzyme activity has previously
been determined in cultured lymphocytes from patients P1,
P3, and P4 (14) (Supplementary Table 1). P1 and P4 showed
a very similar defect in prenylation (Figure 1A) and both
had 8.9% of normal MK activity, whereas P3 with a higher
residual MK enzyme activity (16.4%) had a milder prenylation
defect (Figure 1A).
Analysis of PBMCs from patient P5 (MVKV377I/Y149
150ins
)
revealed a clear defect in Rab and Rap1A prenylation (Figure 1B;
note that P5 is shown alongside P2 for comparison with
Figure 1A). PBMCs from the heterozygous individual P6
(MVKV377I/+) did not have a prenylation defect and appeared the
same as PBMCs from two healthy control volunteers (Figure 1B).
PBMCs from P7 (MVKV377I/Y114Ifs
∗71) had a severe defect in Rab
and Rap1A prenylation (Figure 1C) that was completely absent
in both parents heterozygous for theseMVK variants.
DISCUSSION
We recently proposed that MKD can be identified and
distinguished from other autoinflammatory disorders by the
defect in protein prenylation, and that this defect can be
detected using an in vitro prenylation assay (11) to analyze
PBMC patient samples (12, 13). We now show, with 6
additional, genetically-confirmed MKD patients, that the assay
accurately revealed the accumulation of unprenylated proteins
only in the PBMCs from 6 patients carrying pathogenic/likely
pathogenic MKD variants on both alleles (P1, P2, P3, P4,
P5, and P7—see Supplementary Table 2). Furthermore, the
underlying defect in protein prenylation was still apparent
in PBMCs of 3 patients despite anti-inflammatory treatment
(etanercept or canakinumab) at the time of blood sampling.
Interestingly, heterozygous MVKV377I/+ individual P6 did not
have defective protein prenylation even though she presented
with autoinflammatory disease. This is entirely consistent with
the recessive nature of pathogenic MVK variants (3, 4) and her
symptoms were therefore most likely due to a different disorder.
It remains unclear how the severity of mutations in MVK
correlate with loss of MK enzyme activity and hence the extent
of the defect in protein prenylation. Point mutations that alter
amino acid positions 8–35 and 234–338 (which includes the
mutantMVK alleles in patients P1, P2, P3) affect regions adjacent
to the active site cleft or dimerization interface of MK and
appear to have the most deleterious effect on enzyme folding
or stability (15). Pathogenic variants affecting other regions,
such as the Valine to Isoleucine substitution at position 377
(MVKV377I)—the commonest pathogenic variant in MKD (3, 16,
17)—may render the enzyme temperature-sensitive (4, 18, 19).
We previously found a very mild prenylation defect in a patient
homozygous forMVKV377I (13), a genotype associated with mild
or even absent clinical features (20). In the current study we
found that the prenylation defect appeared more pronounced
in patients with lower residual MK activity (P1, P4), and milder
in a patient (P3) with higher residual MK activity. Furthermore,
patient P7 showed a very profound defect in protein prenylation
and presented with severe clinical symptoms. Hence, at least
in this small group of patients, the extent of the defect in
protein prenylation in PBMCs (as detected in our assay) seems
to correlate with how severely the mutations affect MK enzyme
activity. Because of the rarity of patients with mevalonic aciduria
(the severest form of MKD), we have not yet been able to analyse
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FIGURE 1 | Defective protein prenylation in PBMCs is detected consistently in patients with MKD. (A) PBMCs from four adult, compound heterozygous MKD patients
(P1–P4) have clear accumulation of unprenylated Rab GTPases (uRabs) and unprenylated Rap1A (uRap1) compared to a healthy control (Cntrl) and 2 heterozygous
individuals (Het1,2). (B) PBMCs from a young adult patient with MKD (P5) show accumulation of unprenylated Rab and Rap1A GTPases compared to 2 healthy
controls (Cntrl) and a heterozygous (Het) individual (P6) with undiagnosed inflammatory disease. Patient P2 is also shown alongside for comparison. (C) A child (P7)
with MKD shows a severe defective in Rab and Rap1A prenylation in PBMCs, compared to both unaffected, heterozygous parents (Prnt1,2). Seventy-five kilodalton
endogenous biotinylated protein was used as a loading control in all of the blots.
PBMCs from any of these individuals. However, because MK
enzyme activity is usually undetectable in mevalonic aciduria
patients we would predict that the defect in protein prenylation
in these individuals would be even more dramatic than in HIDS
(the milder form of MKD). Analysis of a larger cohort of patients
is clearly needed to better understand the relationship between
the severity of pathogenic MVK variants, defective prenylation
and clinical symptoms in MKD. Nevertheless, our studies show
that the in vitro prenylation assay described here appears to
be a sensitive and accurate method that could aid, or help
rule out, a specific diagnosis of MKD in patients presenting
with autoinflammatory disease. Finally, it is worth noting that
the analysis of patients P1, P2, P3, and P4 (Figure 1A) was
performed on frozen, viable PBMCs shipped on dry ice to
Australia by courier from the Netherlands, whilst the analysis of
patients P5, P6, and P7 (Figures 1B,C) was performed on freshly-
isolated and snap-frozen cells stored at −80◦C. The results
demonstrate that the in vitro prenylation assay was effective at
detecting the accumulation of unprenylated proteins in both sets
of PBMC samples. Hence, PBMC samples can be collected, stored
and shipped to our institute or elsewhere for analysis without
compromising the accuracy of the results.
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